Pfizer Reveals Positive Results Of Phase 3 PALOMA-2 Clinical Trial Of IBRANCE
April 19, 2016 at 10:14 AM EDT
Pfizer Inc (NYSE: PFE) revealed positive top line results from its stage three PALOMA-2 study for IBRANCE, which is an oral, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.